
🚨 New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics

🌿 Medical Director, Psychiatry, Sattva Medicine 🔬 Psychedelic Therapy Researcher 📚 Baylor College of Medicine You and your experience matter.

🚨 New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics

New in Psychopharmacology: does the experience matter for ketamine? In 3,637 adults with depression, more intense psychedelic experiences went with greater improvement. Observational, but a sign the experience deserves careful measurement. doi.org/10.1007/s00213-026-0…

Esketamine and Acceptance and Commitment Therapy (ACT) for Treatment-Resistant Depression: An Intervention-Development Framework and Treatment Manual doi.org/10.1016/j.psyche.202…

Integrating evidence, subject-matter expertise, and consensus in Delphi-based clinical guideline development: sciencedirect.com/science/ar…

ASKP3 publishes first interdisciplinary consensus standards for IV ketamine treatment in the United States prn.to/4v6GqV0

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3): sciencedirect.com/science/ar…

Reported Safety Practices of Publicly Advertised Psychedelic Retreats jamanetwork.com/journals/jam… I find this study could be a useful springboard for deep discussions around safety and ethics, but NOT only from a western medical lens.

Across #psychedelicretreats, most organizations conducted medical history screening and recommended medication washout, but safety protocols and health professional involvement varied. ja.ma/45tDQh7

🚨 New publication led by the OSU psychedelic center! "𝗨𝗦 𝗱𝗿𝘂𝗴 𝗽𝗼𝗹𝗶𝗰𝘆 𝗱𝗼𝗲𝘀 𝗻𝗼𝘁 𝗮𝗹𝗶𝗴𝗻 𝘄𝗶𝘁𝗵 𝗲𝘅𝗽𝗲𝗿𝘁𝘀’ 𝗿𝗮𝗻𝗸𝗶𝗻𝗴𝘀 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗵𝗮𝗿𝗺𝘀: 𝗔 𝗺𝘂𝗹𝘁𝗶-𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀" link.springer.com/article/10…

DISCLAIMER: This post is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions related to mental health or treatment options.

Link to the pre-proof version of the article: pubmed.ncbi.nlm.nih.gov/4102…

🚨 New paper alert! 🚨 Check out the latest viewpoint by our Dr. McGuire, scholar Dr. Mathai, and collaborators on minimizing risk and harm in the use of psychedelics. Read more: onlinelibrary.wiley.com/doi/… #psychedelics #harmreduction

Lots of people have been speculating about Elon Musk’s ketamine use, and so I wrote about what we do know about prolonged, heavy ketamine use in samples of recreational users. Many of these risks are well-known already in psychedelic circles. theatlantic.com/health/archi…

Today in The Drop In: Beat-era poet and artist Gerd Stern’s final chapter, new research on why guilt during a trip might actually help you heal, and monkeys tapping into plant medicine. Plus, soul retrieval and what to know before working with Datura. newsletter.doubleblindmag.co…

“Bad trips” and guilt: Why difficult feelings during psychedelic use might actually be a good thing: Study @d_mathai @sdpnayak @n_sepeda @Drug_Researcher @JHPsychedelics @BCMEthics @unlimited_sci psypost.org/bad-trips-and-gu…

New publication in the Journal of Psychoactive Drugs led by Dr. David Mathai (@d_mathai) exploring emotions of shame and guilt that may arise during someone's psilocybin experience, and their relevance to psychological outcomes. tandfonline.com/doi/epdf/10.…